22
May

After months of back and forth with regulators yoked its share price up and down, Sarepta Therapeutics is all-in on its odds of winning FDA approval for its Duchenne muscular dystrophy treatment, putting up $25 million for a manufacturing plant to produce the drug.

…read more

Source: Sarepta bets on DMD drug approval with a $25M plant buy

    

0 No comments